Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

VASTox plc (SUMM)

  Print      Mail a friend

Thursday 22 June, 2006

VASTox plc

Orphan Drug Designation

VASTox plc
22 June 2006


Oxford, UK, 22 June 2006 - VASTox (AIM: VOX), a leading chemical genomics
company, announces today that the European Medicines Agency (EMEA) has
recommended awarding orphan drug designation for the company's initial compound
for the treatment of Duchenne muscular dystrophy (DMD).

The orphan drug application has received a positive opinion from the Committee
for Orphan Medicinal Products (COMP) of EMEA. VASTox expects the formal approval
from the European Commission within the next 30 days. The European Commission
has never failed to ratify a positive opinion from EMEA.

Orphan drug designation in Europe provides VASTox with ten years of market
exclusivity following market approval. This protection is in addition to any
intellectual property rights that cover the product which is marketed. In
addition, the designation provides VASTox with support and assistance throughout
the drug development process, including waiving significant regulatory costs
before a drug reaches the market.

EMEA grants orphan drug designation to medical products that satisfy a number of
criteria, including the severity of the disease for which they will be used, the
prevalence of the disease in Europe and the lack of alternative treatments.
Duchenne muscular dystrophy satisfies these criteria and VASTox was able to show
that the company's approach to treat this condition (i.e. the up-regulation of
utrophin) could be of significant benefit to these patients for which there are
at present very limited treatment options.

DMD is the company's most advanced drug development programme. At present the
company is working on selecting a lead drug candidate. This important milestone
is expected to be reached by Q1 2007, with clinical trials forecast to start a
year afterwards.

Steven Lee, PhD, CEO of VASTox said: 'I am very pleased that VASTox has received
this positive opinion from the Committee for Orphan Medicinal Products.
Receiving orphan drug designation is an important step for the company; it
validates our unique approach to the treatment of Duchenne muscular dystrophy
while at the same time it will reduce the costs of developing what we hope will
be a major advance in the treatment of this devastating neuromuscular disease.'

                                    - ends -

For more information please contact:

Steven Lee, PhD, Chief Executive Officer                 Tel: +44 (0)1235 443910
Darren Millington, Chief Financial Officer

Citigate Dewe Rogerson                                  Tel: +44 (0)207 638 9571
David Dible / Mark Swallow / Valerie Auffray

About VASTox plc

VASTox is a chemical genomics technology company that discovers and develops
proprietary novel drugs and provides services to the pharmaceutical industry.
The company's most advanced drug development programme is focused on developing
a new treatment for Duchenne muscular dystrophy based on the up-regulation of
utrophin. A second drug development programme for spinal muscular atrophy is
also progressing rapidly. VASTox has three additional programmes focused on
osteoarthritis, cancer and tuberculosis that are expected to be out-licensed
prior to entering the clinic.

The company's technology platform, which uses zebrafish and fruitflies, has the
potential to dramatically decrease the time and cost of drug discovery and
development. This is because using whole organisms allows it to carry out high
volume, high content screening that delivers data which is highly predictive of
the efficacy and toxicity of potential drug compounds in humans. VASTox is
growing revenues based on marketing its unique technology platform and its
chemistry expertise.  The company listed on the AIM market of the London Stock
Exchange in October 2004.

Further information about the company is available at 

This document contains 'forward-looking statements' within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as 'anticipates', 'intends', 'plans',
'seeks', 'believes', 'estimates', 'expects' and similar references to future
periods, or by the inclusion of forecasts or projections. 

Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements include (factors
included in this presentation) and regional, national, global political,
economic, business, competitive, market and regulatory conditions.

                      This information is provided by RNS
            The company news service from the London Stock Exchange